- Home
- CELC vs SMLR Comparison
CELC vs SMLR Comparison
Compare CELC & SMLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- SMLR
- Stock Information
- Founded
- CELC 2011
- SMLR 2007
- Country
- CELC United States
- SMLR United States
- Employees
- CELC N/A
- SMLR N/A
- Industry
- CELC Medical Specialities
- SMLR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- CELC Health Care
- SMLR Health Care
- Exchange
- CELC Nasdaq
- SMLR Nasdaq
- Market Cap
- CELC 489.7M
- SMLR 556.7M
- IPO Year
- CELC 2017
- SMLR 2014
- Fundamental
- Price
- CELC $12.86
- SMLR $72.77
- Analyst Decision
- CELC Strong Buy
- SMLR
- Analyst Count
- CELC 6
- SMLR 0
- Target Price
- CELC $29.17
- SMLR N/A
- AVG Volume (30 Days)
- CELC 232.9K
- SMLR 1.2M
- Earning Date
- CELC 11-14-2024
- SMLR 11-04-2024
- Dividend Yield
- CELC N/A
- SMLR N/A
- EPS Growth
- CELC N/A
- SMLR N/A
- EPS
- CELC N/A
- SMLR 2.04
- Revenue
- CELC N/A
- SMLR $58,938,000.00
- Revenue This Year
- CELC N/A
- SMLR N/A
- Revenue Next Year
- CELC N/A
- SMLR N/A
- P/E Ratio
- CELC N/A
- SMLR $36.55
- Revenue Growth
- CELC N/A
- SMLR N/A
- 52 Week Low
- CELC $11.51
- SMLR $20.88
- 52 Week High
- CELC $22.19
- SMLR $81.56
- Technical
- Relative Strength Index (RSI)
- CELC 42.58
- SMLR 65.89
- Support Level
- CELC $11.94
- SMLR $58.75
- Resistance Level
- CELC $13.14
- SMLR $81.56
- Average True Range (ATR)
- CELC 0.51
- SMLR 6.92
- MACD
- CELC 0.07
- SMLR 0.46
- Stochastic Oscillator
- CELC 58.70
- SMLR 69.54
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About SMLR Semler Scientific Inc.
Semler Scientific Inc is a United States based company that is engaged in providing technology solutions to improve the clinical effectiveness and efficiency of healthcare providers. It focuses on developing, manufacturing, and marketing proprietary products and services that assist customers, including insurance plans, physicians, and risk assessment groups, in evaluating and treating chronic diseases. The company markets its vascular-testing product under the QuantaFlo brand, which is a four-minute in-office blood flow test.